When you think about pot stocks, the names Canopy Growth Corp., Aphria Inc. and Aurora Cannabis Inc. probably spring to mind, as they are the three largest Canadian marijuana companies and are widely covered.
Let me present another pot stock that began trading on the TSX on June 22 that’s worth a look: Hydropothecary Corp. (TSX:HEXO).
A small pot producer with big ambitions
Hydropothecary is Quebec’s largest medical marijuana producer. The company is much smaller than Canopy Growth, Aphria and Aurora, with a market capitalization of around $1 billion. But Hydropothecary wants to gain market share and eventually become one of the world’s two largest marijuana companies.
The pot producer is on the lookout for acquisitions in an industry that is consolidating quickly. The company is targeting licensed producers who have supply contracts with buyers in other provinces, or companies that offer advanced technologies to develop new cannabis-based products. Hydropothecary is also interested in expanding in the United States and Europe.
The company offers four product lines. Two of these lines consist of dried cannabis buds: Time of Day, their signature line, and H2, their classic line.
For people who don’t want to inhale cannabis smoke, it has developed two innovative and smoke-free product lines: Elixir, a sublingual spray of cannabis oil, and Decarb, an orally activated cannabis. These two products won awards for Best New Cannabis Product at the Canadian Cannabis Awards gala last year.
Increased production in preparation for the recreational market
The Gatineau-based company reported its fiscal 2018 third-quarter results last week. Its revenue increased 5% to $1.2 million compared to the same period a year earlier, and its revenue per gram increased to $9.24 from $8.62, the highest in the industry.
The cash cost of dried cannabis sold per gram was $0.88, a decrease of 57% compared to the third quarter of fiscal 2017, making it one of the country’s lowest-cost producers.
The company had cash and short-term investments of $248.9 million as at April 30 and no debt on its balance sheet.
Loss from operations was $2.65 million in the third quarter, compared to $1 million for the same quarter a year earlier. The increased loss from operations is due mostly to higher expenses incurred by the company to expand its operations in preparation of the legalization of the cannabis recreational market.
Hydropothecary incurred a net loss of $1.97 million or $0.01 per share in the quarter, compared to a net loss of $11.81 million, or $0.17 per share a year ago.
The Quebec company currently operates with 300,000 square feet of production capacity and will expand its greenhouses by 1 million square feet by the end of the year. These expansions will increase its cannabis production from 3,600 kg to 108,000 kg per year.
In April, Hydropothecary signed a five-year agreement to supply the Société des alcools du Québec (SAQ) with up to 200,000 kg of cannabis.
According to CEO Sebastien St-Louis, this agreement will give the company the second highest recreational revenue among licensed producers for the first year of the recreational market in Canada and 35% of Quebec’s recreational market share.
Hydropothecary plans to change its corporate name for HEXO to match the brand name under which the company will be selling its recreational cannabis products.
Over the last year, Hydropothecary’s share price has risen by almost 300%. The stock entry on the TSX should increase its valuation.
I think that this small pot producer has big potential. Hydropothecary is one of the lowest-cost producers and is offering unique products that attract consumers. The company is also well prepared to face the recreational market by rapidly increasing its production capacity.
According to estimates, the company’s revenue could increase more than 1,800% to about $100 million in 2019 and earnings could rise 150% to $0.06 per share. It’s time to buy shares of Hydropothecary before the market recognizes its full potential.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.
Fool contributor Stephanie Bedard-Chateauneuf owns shares of AURORA CANNABIS INC, Canopy Growth, and THE HYDROPOTHECARY CORPORATION.